Information  X 
Enter a valid email address

Byotrol PLC (BYOT)

  Print          Annual reports

Tuesday 19 May, 2020

Byotrol PLC

Holding(s) in Company

RNS Number : 3666N
Byotrol PLC
19 May 2020
 

 

 

 

 

Byotrol plc ("Byotrol" or the "Company")

 

Holdings in the Company

 

Byotrol plc (AIM:BYOT), the specialist infection prevention and control technology company, announces that it has received notification that as of 15 May 2020, Mr V P and Mrs N M Silvester hold 14,000,000 shares of 0.25 pence each in the Company, representing 3.18% of the Company's issued share capital. 

 

 

Enquiries:

 

Byotrol plc 

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer  01925 742 000

 

finnCap

Geoff Nash/Kate Bannatyne - Corporate Finance                               020 7220 0500

Richard Chambers - ECM

 

Flagstaff Strategic and Investor Communications

Tim Thompson/Andrea Seymour/Fergus Mellon   +44 (0)207 129 1474

[email protected]

 

 

 

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLKKCBKDBKDAPD

a d v e r t i s e m e n t